Translarna received conditional approval in Europe in 2014 for the treatment of nonsense mutation DMD patients who are in ambulatory state and are 5 years or older. Exondys51 and Emflaza have not been approved for DMD treatment in Europe
From the article above.
Proves what Sam and I said earlier
The 2 Sarepta drugs have not been approved for DMD in Europe..
So what some might say
Well it tells the true believers it took Anp 2 years to get approval from the EMA and PIP for Atl1102 Re DMD to get validation…
So the Science is there!! We just need to sell the story in the US
$5 in time
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data, page-352
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.5¢ | 7.8¢ | 7.5¢ | $2.881K | 37.29K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 230 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 120000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.8¢ | 7.5¢ | 100937 | ||
| Last updated 15.33pm 13/05/2024 ? | |||||
| PER (ASX) Chart |